Joseph Sgouros

Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer

Anthony Maraveyas, Justin S. Waters, Rajarshi Roy et al. · European Journal of Cancer · 2011 · 314 citations · Full text

Pancreatic Cancer, Medicine, Gemcitabine Versus Gemcitabine +4

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes

George Pentheroudakis, Vassiliki Kotoula, Wendy De Roock et al. · BMC Cancer · 2013 · 111 citations · Full text

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis

Dimitrios Pectasides, George Papaxoinis, Konstantine T. Kalogeras et al. · BMC Cancer · 2012 · 76 citations · Full text

Vascular endothelial growth factor polymorphisms and clinical outcome in colorectal cancer patients treated with irinotecan-based chemotherapy and bevacizumab

Anna G. Antonacopoulou, Anastasia G Eleftheraki, Foteinos‐Ioannis Dimitrakopoulos et al. · The Pharmacogenomics Journal · 2011 · 75 citations

Medicine, Colorectal Cancer, Pathology +7

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer

Dimitrios Pectasides, Vasilios Karavasilis, George Papaxoinis et al. · BMC Cancer · 2015 · 51 citations · Full text